![]() In the case of COVID-19 J&J/Janssen vaccine, the risk is minimal however, people with a history of GBS may opt to receive an mRNA version of COVID-19 vaccine. In the case of shingles vaccine, this is because of age differences between recommended vaccine receipt and increased risk of GBS. While the shingles vaccine (Shingrix ®) and the J&J/Janssen COVID-19 vaccines have both been associated with GBS on occasion, specific recommendations related to history of GBS are not in place. ![]() If a person developed GBS within six weeks of receipt of a tetanus-containing vaccine, they have a precaution related to future receipt of tetanus-containing vaccines, but if their bout of GBS did not occur within six weeks of a tetanus vaccination, they can be vaccinated. Similar recommendations are in place for tetanus-containing vaccines. Other people with a history of GBS (i.e., GBS that did not occur within six weeks of getting an influenza vaccine) can receive influenza vaccine. A “precaution” means that the patient and their healthcare provider should weigh the relative risks and benefits of the vaccine versus disease to decide which is the less risky choice. Unfortunately, people with a history of GBS are often under the impression that they cannot get the influenza vaccine, but the recommendations by the Centers for Disease Control and Prevention, only suggest a “precaution” for influenza vaccination if someone developed GBS within six weeks of receipt of an influenza vaccine. Therefore, one could reasonably argue that influenza vaccine prevents GBS. The attributable risks were one GBS admission per million vaccinations compared with 17 GBS admissions per million influenza infections. They found that the risk of GBS within six weeks of an influenza illness was much greater than after influenza vaccination. For example, Canadian researchers assessed the risk of GBS after seasonal influenza vaccination in Ontario, Canada, between 19. Since that time, the relationship between influenza vaccine and GBS has been variable. At the time, the estimated risk of GBS following receipt of the swine flu vaccine was estimated to be about 1 per 100,000 recipients. The notion that Guillain-Barre syndrome (GBS) could be a consequence of vaccination was born of the swine influenza vaccine program administered in the United States in 1976.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |